Compare UFI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | KZIA |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.9M | 74.4M |
| IPO Year | N/A | 1999 |
| Metric | UFI | KZIA |
|---|---|---|
| Price | $3.98 | $7.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 85.3K | ★ 257.7K |
| Earning Date | 02-04-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $559,646,000.00 | $1,199,108.00 |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $12.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.96 | $2.86 |
| 52 Week High | $6.49 | $17.40 |
| Indicator | UFI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 45.63 |
| Support Level | $3.77 | $6.07 |
| Resistance Level | $3.99 | $7.08 |
| Average True Range (ATR) | 0.20 | 0.83 |
| MACD | 0.06 | 0.08 |
| Stochastic Oscillator | 85.44 | 82.28 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.